Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    5
ATC Name B/G Ingredients Dosage Form Price
B01AF01 VAROXA G Rivaroxaban - 10mg 10mg Tablet, film coated 2,879,854 L.L
B01AF01 VAROXA G Rivaroxaban - 15mg 15mg Tablet, film coated 1,343,843 L.L
B01AF01 VAROXA G Rivaroxaban - 20mg 20mg Tablet, film coated 1,343,843 L.L
C09DX04 VALBITRYL 24/26 G Sacubitril - 24mg, Valsartan - 26mg Tablet, film coated 5,490,557 L.L
C09DX04 VALBITRYL 49/51 G Sacubitril - 49mg, Valsartan - 51mg Tablet, film coated 5,490,557 L.L
C09DX04 VALBITRYL 97/103 G Sacubitril - 97mg, Valsartan - 103mg Tablet, film coated 10,531,062 L.L
R03AC02 VENTOLIN EVOHALER B Salbutamol (sulfate) - 100mcg/dose 100mcg/dose Inhalation aerosol metered dose 260,705 L.L
R03AC02 VENTOLIN B Salbutamol (sulfate) - 5mg/ml 5mg/ml Solution 403,153 L.L
G04BE03 VIAGRA B Sildenafil (citrate) - 100mg 100mg Tablet, film coated 2,089,675 L.L
G04BE03 VIAGRA B Sildenafil (citrate) - 50mg 50mg Tablet, film coated 2,089,675 L.L
G04BE03 VIGOR-50 G Sildenafil (citrate) - 50mg 50mg Tablet, film coated 332,761 L.L
G04BE03 VIRECTA G Sildenafil - 100mg 100mg Tablet, film coated 584,571 L.L
G04BE03 VIADIS G Sildenafil - 50mg 50mg Tablet, film coated 325,210 L.L
G04BE03 VIGORAM G Sildenafil citrate - 50mg 50mg Tablet 330,585 L.L
G04BE03 VONTA G Sildenafil citrate - 50mg 50mg Tablet, film coated 335,961 L.L
G04BE03 VONTA G Sildenafil citrate - 50mg 50mg Tablet, film coated 90,037 L.L
C10AA01 VASCOR G Simvastatin - 10mg 10mg Tablet, scored 284,127 L.L
C10AA01 VASCOR G Simvastatin - 20mg 20mg Tablet, scored 284,127 L.L
C10AA01 VASCOR G Simvastatin - 40mg 40mg Tablet, scored 284,127 L.L
N03AG01 VILAPRO CHRONO 500 G Sodium valproate - 333mg, Valproic acid - 145mg Tablet, film coated, prolonged release 217,702 L.L
N03AG01 VALPROATE DE SODIUM ARROW LP G Sodium valproate - 500mg 500mg Tablet, coated, scored, prolonged release 253,986 L.L
J05AP56 VOSEVI B Sofosbuvir - 400mg, Velpatasvir - 100mg, Voxilaprevir - 100mg Tablet, film coated 891,634,849 L.L
G04BD08 VESICARE B Solifenacin succinate - 10mg 10mg Tablet, film coated 1,619,330 L.L
G04BD08 VESICARE B Solifenacin succinate - 5mg 5mg Tablet, film coated 1,619,330 L.L
B05AA07 VOLUVEN B Starch poly(O-2-Hydroxyethyl) - 6% 6% Injectable solution 987,724 L.L
B01AB11 VESSEL DUE F TAB. B Sulodexide - 250LRU 250LSU Capsule, soft gelatin 2,792,505 L.L
N07XX08 VYNDAMAX B Tafamidis - 61mg 61mg Capsule 784,020,041 L.L
G04CA53 VESOMNI B Tamsulosin HCl - 0.4mg, Solifenacin succinate - 6mg Tablet, modified release 4,491,122 L.L
J05AF13 VEMLIDY B Tenofovir alafenamide fumarate - 25mg 25mg Tablet, film coated 26,997,299 L.L
J05AF07 VIREAD B Tenofovir disoproxil - 245mg 245mg Tablet, film coated 15,716,313 L.L
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2026